Table 2.
Summary table of ongoing clinical trials carried out on NTG in cancer therapy.
| Stage | Patient number | Associated treatment | Method of administeringNTG | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| Non-small cell lung cancer (NSCLC) | ||||
| Phase II | ||||
| Previously untreated stage IIIB/IV NSCLC | 150 | Paclitaxel and Carboplatin (6 cycles) | NTG patch | NCT00616031 |
| NSCLC with brain metastases | 96 | Whole brain radiation therapy (WBRT) | NGT patch (36 mg from monday through friday throughout WBRT administration (10 days)) | NCT04338867 |
| Prostate cancer | ||||
| Phase III | ||||
| Biochemical recurrence of prostate cancer after primary therapy | 60 | Surgery or radiotherapy | NTG patch (0.0285 mg/h or 0.057 mg/h) | NCT01704274 |